Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $130.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 37.52% to $130.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $640.5 million, a 25.31% increase, with the full-year FY2025 number at $130.9 million, down 37.52% from a year prior.
  • Liabilities and Shareholders Equity was $130.9 million for Q4 2025 at Artiva Biotherapeutics, down from $148.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $225.6 million in Q3 2024 to a low of $75.9 million in Q2 2024.
  • A 3-year average of $157.1 million and a median of $159.1 million in 2025 define the central range for Liabilities and Shareholders Equity.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 123.14% in 2025; the steepest drop was 37.52% in 2025.
  • Artiva Biotherapeutics' Liabilities and Shareholders Equity stood at $105.1 million in 2023, then skyrocketed by 99.38% to $209.6 million in 2024, then plummeted by 37.52% to $130.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Liabilities and Shareholders Equity are $130.9 million (Q4 2025), $148.9 million (Q3 2025), and $169.4 million (Q2 2025).